Pacific Biosciences of California (PACB) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PACB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PACB, but not buy additional shares or sell existing shares.
View PACB analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1-year price targets for Pacific Biosciences of California's shares. Their PACB share price forecasts range from $8.00 to $15.00. On average, they predict the company's share price to reach $12.75 in the next twelve months. This suggests a possible upside of 2.2% from the stock's current price.
View analysts price targets for PACB or view top-rated stocks among Wall Street analysts.

Pacific Biosciences of California's stock was trading at $8.18 on January 1st, 2023. Since then, PACB shares have increased by 52.6% and is now trading at $12.48.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our PACB earnings forecast.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.02. The biotechnology company earned $38.90 million during the quarter, compared to analyst estimates of $34.38 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 47.46% and a negative net margin of 239.32%. Pacific Biosciences of California's revenue for the quarter was up 17.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.37) earnings per share.

ETFs with the largest weight of Pacific Biosciences of California (NASDAQ:PACB) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), Global X Telemedicine & Digital Health ETF (EDOC), AXS Green Alpha ETF (NXTE), ARK Innovation ETF (ARKK), AltShares Event-Driven ET (EVNT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Horizon Kinetics Medical ETF (MEDX).

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.20%), BlackRock Inc. (8.08%), Sumitomo Mitsui Trust Holdings Inc. (5.61%), Nikko Asset Management Americas Inc. (5.61%), Jackson Square Partners LLC (4.84%) and Farallon Capital Management LLC (2.54%). Insiders that own company stock include Christian O Henry, Eric Schaefer, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Michele Farmer, Oene Mark Van, Peter Fromen, Susan G Kim and William W Ericson.
View institutional ownership trends.

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PACB stock can currently be purchased for approximately $12.48.

Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $3.12 billion and generates $128.30 million in revenue each year. The biotechnology company earns $-314,250,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

The company employs 728 workers across the globe.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454.